https://scholars.lib.ntu.edu.tw/handle/123456789/458694
Title: | Enhancement of sindbis virus self-replicating RNA vaccine potency by targeting antigen to endosomal/lysosomal compartments | Authors: | WEN-FANG CHENG Hung C.-F. Hsu K.-F. Chai C.-Y. He L. Ling M. Slater L.A. Roden R.B.S. Wu T.-C. |
Issue Date: | 2001 | Journal Volume: | 12 | Journal Issue: | 3 | Start page/Pages: | 235-252 | Source: | Human Gene Therapy | Abstract: | Self-replicating RNA vaccines (RNA replicons) have emerged as an attractive approach for tumor immunotherapy. RNA replicons do not integrate into host chromosomes, eliminating the concern for oncogenicity associated with a DNA vaccine. In this study, we used human papillomavirus type 16 (HPV-16) E7 as a model antigen and evaluated E7-specific immunity generated by a Sindbis virus self-replicating RNA vector, SIN-rep5. Three different constructs were created to target E7 antigen to different cellular localizations: (1) E7, a cytosolic/nuclear protein; (2) Sig/E7, a secretory protein; (3) Sig/E7/LAMP-1, in which we linked the transmembrane and cytoplasmic regions of the lysosome-associated membrane protein 1 (LAMP-1) to E7 protein to target E7 to the endosomal/lysosomal compartment. We found that the RNA replicon vaccine containing the Sig/E7/LAMP-1 fusion gene generated the highest E7-specific T cell-mediated immune responses and antitumor effects relative to RNA vaccines containing either wild-type E7 or Sig/E7. Our in vitro studies demonstrated that E7 antigen from Sig/E7/LAMP-1 RNA replicon-transfected apoptotic cells can be taken up by bone marrow-derived dendritic cells (DCs) and presented more efficiently through the MHC class I pathway than wild-type E7 RNA replicon-transfected apoptotic cells. Furthermore, our data revealed that CD8+ T cells, CD4+ T cells, and NK cells were important for the antitumor effects generated by Sig/E7/LAMP-1 RNA vaccination. These results indicate that targeting antigen to the endosomal/lysosomal compartment via fusion to LAMP-1 may greatly enhance the potency of self-replicating RNA vaccines. |
URI: | 2-s2.0-0035835376 https://scholars.lib.ntu.edu.tw/handle/123456789/458694 |
ISSN: | 1043-0342 | DOI: | 10.1089/10430340150218387 | SDG/Keyword: | DNA vaccine; major histocompatibility antigen class 1; membrane protein; virus antigen; virus vaccine; animal cell; animal experiment; antineoplastic activity; article; cancer immunotherapy; controlled study; dendritic cell; drug potency; endosome; female; fusion gene; gene targeting; immune response; lysosome; mouse; natural killer cell; nonhuman; replicon; Sindbis virus; T lymphocyte; virus replication; Wart virus; Animals; Antigens, CD; Apoptosis; Bone Marrow Cells; Cancer Vaccines; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Line; Cell Membrane; Cricetinae; Dendritic Cells; DNA; Endosomes; Enzyme-Linked Immunosorbent Assay; Female; Flow Cytometry; Genes, MHC Class I; Humans; In Situ Nick-End Labeling; Killer Cells, Natural; Lysosome-Associated Membrane Glycoproteins; Lysosomes; Membrane Glycoproteins; Mice; Mice, Inbred C57BL; Neoplasms; Oncogene Proteins, Viral; Phagocytosis; Plasmids; Sindbis Virus; Spleen; T-Lymphocytes, Cytotoxic; Time Factors; Transfection; Vaccines, DNA; Animalia; Human papillomavirus; Human papillomavirus type 16; Human papillomavirus types; Sindbis virus |
Appears in Collections: | 醫學系 |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.